SCHEMBL759280

SCHEMBL759280

CN(C)c1cccc(C(=O)Nc2n[nH]c3ccc([N+](=O)[O-])cc23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.55
ABCG2 Q9UNQ0 1/20 0.45
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
PKM P14618 1/20 0.45
NTRK1 P04629 2/20 0.45
IRAK4 Q9NWZ3 2/20 0.45
CDK7 P50613 4/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 1/20 0.44
CDC7 O00311 1/20 0.43
DAPK3 O43293 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
PRKACA P17612 1/20 0.43
FLT3 P36888 1/20 0.43
CSNK1A1 P48729 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14404444 0.91 MEN1 (0.46) CDK2KMT2AMEN1NPC1RAB9A
SCHEMBL4008807 0.85 CDK2 (0.70) CDK2ABCG2KMT2AMEN1NPC1
SCHEMBL18812705 0.84 CDK2 (0.58) CDK2ABCG2KMT2AMEN1NPC1
SCHEMBL760581 0.83 ULK1 (0.53) CDK2KMT2AMEN1NPC1RAB9A
SCHEMBL18812669 0.78 HDAC6 (0.57) CDK2KMT2AMEN1NPC1RAB9A
SCHEMBL1461245 0.78 CDK2 (0.65) CDK2KMT2AMEN1PKMMAPT
SCHEMBL16164183 0.76 CDK2 (0.70) CDK2KMT2AMEN1PKMMAPT
SCHEMBL6787077 0.76 MEN1 (0.75) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL14404446 0.74 CDK7 (0.58) CDK2IRAK4CDK7CDC7DAPK3
SCHEMBL1336378 0.74 NTRK1 (0.57) CDK2ABCG2KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
CN-101437519-A Indazole compounds ABBOTT LAB (US) 2009-05-20 CN disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 CDK2 790/4885ABCG2 34/4885KMT2A 3965/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 CDK2 790/4885ABCG2 34/4885KMT2A 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.